Loading...

PhaseBio Pharmaceuticals

DB:2K4
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2K4
DB
$390M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
  • PhaseBio Pharmaceuticals has significant price volatility in the past 3 months.
2K4 Share Price and Events
7 Day Returns
-3.7%
DB:2K4
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-
DB:2K4
-10.2%
DE Biotechs
-6%
DE Market
2K4 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
PhaseBio Pharmaceuticals (2K4) -3.7% 127.4% 275.3% - - -
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • No trading data on 2K4.
  • No trading data on 2K4.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is PhaseBio Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for PhaseBio Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €12.234.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for PhaseBio Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are PhaseBio Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2K4 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-4.49
NasdaqGM:PHAS Share Price ** NasdaqGM (2019-04-18) in USD $13.88
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of PhaseBio Pharmaceuticals.

DB:2K4 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:PHAS Share Price ÷ EPS (both in USD)

= 13.88 ÷ -4.49

-3.09x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PhaseBio Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • PhaseBio Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does PhaseBio Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:2K4 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.09x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-32.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for PhaseBio Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on PhaseBio Pharmaceuticals's assets?
Raw Data
DB:2K4 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.08
NasdaqGM:PHAS Share Price * NasdaqGM (2019-04-18) in USD $13.88
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:2K4 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:PHAS Share Price ÷ Book Value per Share (both in USD)

= 13.88 ÷ 2.08

6.68x

* Primary Listing of PhaseBio Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PhaseBio Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess PhaseBio Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. PhaseBio Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is PhaseBio Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-32.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is PhaseBio Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare PhaseBio Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare PhaseBio Pharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • PhaseBio Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:2K4 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2K4 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -32.3%
DB:2K4 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 72.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2K4 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2K4 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 136 8 -121 2
2022-12-31 39 -29 -186 2
2021-12-31 0 -49 -95 2
2020-12-31 0 -42 -53 3
2019-12-31 0 -41 -37 3
DB:2K4 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -17 -24
2018-09-30 0 -13 -22
2018-06-30 0 -5 -16
2018-03-31 -7 -7
2017-12-31 -8 -10
2016-12-31 -10 -9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • PhaseBio Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • PhaseBio Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2K4 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from PhaseBio Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2K4 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -2.20 -2.20 -2.20 1.00
2022-12-31 -3.65 -3.65 -3.65 1.00
2021-12-31 -2.10 -2.10 -2.10 1.00
2020-12-31 -1.70 -1.41 -2.08 3.00
2019-12-31 -1.62 -1.33 -2.03 3.00
DB:2K4 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -4.49
2018-09-30 -28.76
2018-06-30 -21.71
2018-03-31 -9.81
2017-12-31 -13.78
2016-12-31 -12.41

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if PhaseBio Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess PhaseBio Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
PhaseBio Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has PhaseBio Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare PhaseBio Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • PhaseBio Pharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare PhaseBio Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare PhaseBio Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
PhaseBio Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from PhaseBio Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2K4 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.67 -23.85 4.86
2018-09-30 0.41 -21.51 3.63 5.82
2018-06-30 0.00 -16.17 3.14 5.82
2018-03-31 -7.28 2.50 4.64
2017-12-31 -10.25 2.33
2016-12-31 -9.22 2.51 6.99

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if PhaseBio Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if PhaseBio Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if PhaseBio Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess PhaseBio Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
PhaseBio Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is PhaseBio Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up PhaseBio Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • PhaseBio Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • PhaseBio Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of PhaseBio Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 8.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from PhaseBio Pharmaceuticals Company Filings, last reported 3 months ago.

DB:2K4 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 50.93 7.50 61.03
2018-09-30 15.43 7.50 24.34
2018-06-30 -16.04 19.63 8.73
2018-03-31 -16.04 19.63 8.73
2017-12-31 -6.13 15.48 13.41
2016-12-31 3.27 0.00 3.72
  • PhaseBio Pharmaceuticals's level of debt (14.7%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if PhaseBio Pharmaceuticals's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • PhaseBio Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
  • PhaseBio Pharmaceuticals has sufficient cash runway for 2.9 years if free cash flow continues to grow at historical rates of 24.9% each year.
X
Financial health checks
We assess PhaseBio Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. PhaseBio Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is PhaseBio Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from PhaseBio Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of PhaseBio Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate PhaseBio Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate PhaseBio Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2K4 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2K4 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as PhaseBio Pharmaceuticals has not reported any payouts.
  • Unable to verify if PhaseBio Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of PhaseBio Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as PhaseBio Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of PhaseBio Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess PhaseBio Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can PhaseBio Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. PhaseBio Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of PhaseBio Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jonathan Mow
COMPENSATION $436,197
AGE 53
TENURE AS CEO 4.1 years
CEO Bio

Mr. Jonathan P. Mow, MBA has been Chief Executive Officer of PhaseBio Pharmaceuticals, Inc. since March 2015 and serves as its President. Mr. Mow served as Chief Business Officer of PhaseBio Pharmaceuticals, Inc since December 4, 2012. He served as Vice President of Commercial and Business Development and Secretary of Corus Pharma Inc. since January 2001. From January 2001 to February 2003, Mr. Mow served as Senior Director of Business Development of PathoGenesis Corporation, which was acquired by Chiron Corporation in September 2000. From 1995 to January 1997, he served as Director, Worldwide Oncology Strategic Business Planning at Bristol-Myers Squibb Company, a pharmaceutical company. From 1992 to 1995, Mr. Mow served in several positions at American Cyanamid Company, Lederle International Division, a pharmaceutical company, most recently as International Product Manager. From 1990 to 1992, Mr. Mow served as Marketing Research Analyst and Sales Representative of Syntex Laboratories, Inc. Mr. Mow has extensive experience in pharmaceutical marketing and business development. As co-founder of Corus Pharma, he was an integral member of the management team that positioned its aerosol drug pipeline to be acquired for approximately $420 million by Gilead Sciences in 2006. He serves as a Director of PhaseBio Pharmaceuticals, Inc. He served as a Director of AerovectRx Corporartion since February 2, 2007. He served as a Director of Corus Pharma Inc. from January 1997 to December 2000. Mr. Mow received his B.S. degree from University of California Berkeley and his M.S. (M.B.A.) degree from Carnegie Mellon University.

CEO Compensation
  • Insufficient data for Jonathan to compare compensation growth.
  • Jonathan's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the PhaseBio Pharmaceuticals management team in years:

3
Average Tenure
53
Average Age
  • The tenure for the PhaseBio Pharmaceuticals management team is about average.
Management Team

Jonathan Mow

TITLE
President
COMPENSATION
$436K
AGE
53
TENURE
4.1 yrs

John Sharp

TITLE
Chief Financial Officer
COMPENSATION
$368K
AGE
53
TENURE
3 yrs

John Lee

TITLE
Chief Medical Officer
COMPENSATION
$370K
AGE
50
TENURE
3 yrs

Clay Thorp

TITLE
Chairman of the Board
AGE
50

Michael York

TITLE
Vice President of Corporate Development & Commercial Strategy
AGE
53
TENURE
0.8 yrs

Glen Burkhardt

TITLE
Vice President of Human Resources
Board of Directors Tenure

Average tenure and age of the PhaseBio Pharmaceuticals board of directors in years:

1.1
Average Tenure
52
Average Age
  • The average tenure for the PhaseBio Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jonathan Mow

TITLE
President
COMPENSATION
$436K
AGE
53
TENURE
4.6 yrs

Clay Thorp

TITLE
Chairman of the Board
AGE
50

Nancy Hutson

TITLE
Director
AGE
69
TENURE
1.1 yrs

Caroline Loewy

TITLE
Director
AGE
51
TENURE
0.8 yrs

Peter Klein

TITLE
Director
AGE
40
TENURE
9.3 yrs

Linda Tufts

TITLE
Director
AGE
64
TENURE
1.1 yrs

Bibhash Mukhopadhyay

TITLE
Director
AGE
37
TENURE
1.2 yrs

Ed Harrigan

TITLE
Director
AGE
65
TENURE
0.3 yrs

Rich van den Broek

TITLE
Director
AGE
52
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
17. Dec 18 Buy Jonathan Mow Individual 13. Dec 18 13. Dec 18 1,000 €3.25 €3,250
17. Dec 18 Buy D. Ballance Individual 13. Dec 18 13. Dec 18 1,000 €3.47 €3,470
17. Dec 18 Buy Nancy Hutson Individual 17. Dec 18 17. Dec 18 1,000 €3.93 €3,931
13. Dec 18 Buy Jonathan Mow Individual 07. Dec 18 10. Dec 18 1,500 €3.42 €5,105
11. Dec 18 Buy Michael York Individual 11. Dec 18 11. Dec 18 1,500 €3.43 €5,140
11. Dec 18 Buy John Sharp Individual 07. Dec 18 07. Dec 18 5,000 €3.37 €16,846
06. Dec 18 Buy Clay Thorp Individual 04. Dec 18 04. Dec 18 4,000 €2.76 €11,026
24. Oct 18 Buy New Enterprise Associates Company 22. Oct 18 22. Oct 18 1,800,000 €4.36 €7,848,900
24. Oct 18 Buy Fletcher Spaght Ventures, LP Company 22. Oct 18 22. Oct 18 20,000 €4.36 €87,210
24. Oct 18 Buy Hatteras Venture Partners Company 22. Oct 18 22. Oct 18 300,000 €4.36 €1,308,150
24. Oct 18 Buy AstraZeneca PLC Company 22. Oct 18 22. Oct 18 600,000 €4.36 €2,616,300
X
Management checks
We assess PhaseBio Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. PhaseBio Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.

Details
Name: PhaseBio Pharmaceuticals, Inc.
2K4
Exchange: DB
Founded: 2002
$346,235,173
28,084,775
Website: http://www.phasebio.com
Address: PhaseBio Pharmaceuticals, Inc.
1 Great Valley Parkway,
Suite 30,
Malvern,
Pennsylvania, 19355,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM PHAS Common Stock Nasdaq Global Market US USD 18. Oct 2018
DB 2K4 Common Stock Deutsche Boerse AG DE EUR 18. Oct 2018
Number of employees
Current staff
Staff numbers
23
PhaseBio Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 22:56
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/03/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.